Beta Bionics (BBNX) CCO gets equity awards, sells shares for taxes

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported new equity awards and a small share sale. He received a grant of 109,105 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan and 58,749 stock options, which vest in 36 equal monthly installments starting on March 1, 2026.

On March 2, 2026, he sold 834 shares of common stock in an open-market transaction at a weighted average price of $12.3616, in a price range between $12.20 and $12.55, to cover tax withholding obligations tied to restricted stock unit vesting. After this sale, he directly owned 139,486 shares of common stock.

Insider Trade Summary

Net Seller: 834 shares ($10,310)

Net Sell 3 txns

Insider Hopman Mark

Role Chief Commercial Officer

Sold 834 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	834	$12.3616	$10K
Grant/Award	Employee Stock Option (right to buy)	58,749	$0.00	--
Grant/Award	Common Stock	109,105	$0.00	--

Holdings After Transaction: Common Stock — 139,486 shares (Direct); Employee Stock Option (right to buy) — 58,749 shares (Direct)

Footnotes (1)

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		109,105(1)	A	$0	140,320	D
Common Stock	03/02/2026		S(2)		834	D	$12.3616(3)	139,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		58,749		(4)	02/26/2036	Common Stock	58,749	$0	58,749	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

2. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Beta Bionics (BBNX) Chief Commercial Officer Mark Hopman report?

Mark Hopman reported new equity awards and a small sale. He received 109,105 restricted stock units and 58,749 stock options, and sold 834 common shares in an open-market transaction to cover tax withholding obligations from restricted stock unit vesting.

How many Beta Bionics (BBNX) shares did Mark Hopman sell and at what price?

Mark Hopman sold 834 shares of Beta Bionics common stock. The weighted average sale price was $12.3616 per share, with individual sale prices ranging between $12.20 and $12.55, according to the disclosed transaction pricing footnote.

Why did Mark Hopman sell Beta Bionics (BBNX) shares in this Form 4 filing?

The filing states the 834 shares were sold to cover tax withholding obligations. These obligations were associated with the vesting of restricted stock units, making the sale a tax-related disposition rather than a discretionary liquidation of investment holdings.

What equity awards did Mark Hopman receive from Beta Bionics (BBNX)?

Mark Hopman received 109,105 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan. He was also granted 58,749 stock options that vest in 36 equal monthly installments beginning March 1, 2026, providing long-term equity-based compensation.

How many Beta Bionics (BBNX) shares does Mark Hopman own after these transactions?

After the reported transactions, Mark Hopman directly owned 139,486 shares of Beta Bionics common stock. This post-transaction figure reflects his holdings following the 834-share sale executed to satisfy tax withholding tied to restricted stock unit vesting.

How do Mark Hopman’s new stock options in Beta Bionics (BBNX) vest?

The 58,749 stock options granted to Mark Hopman vest in 36 equal monthly installments. Vesting is measured from March 1, 2026, creating a three-year vesting schedule that gradually delivers exercisable options over that period, as described in the option footnote.